Passage Bio Alternatives & Competitors
12 companies similar to Passage Bio — Our mission is to improve the lives of patients with neurodegenerative diseases
Companies similar to Passage Bio
Lexeo Therapeutics
Advancing science with curative potential for both cardiovascular and APOE4 associated Alz...
VBL Therapeutics (Nasdaq:VBLT)
Engineering the future of targeted medicines, breaking barriers to develop the next genera...
ProJenX
ProJenX is a clinical-stage biotech developing novel, brain-penetrant MAP4K inhibitors for...
HuidaGene Therapeutics
辉大,给患者回答 | Answering the Patients!
Rival Readout
Competing with Passage Bio? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Spinogenix, Inc.
Developing a new class of therapeutics for neurodegenerative and psychiatric diseases
GenSight Biologics
Applying pathbreaking science to transform the lives of patients with severe retinal neuro...
Cognition Therapeutics, Inc.
Advancing Accessible Solutions for Complex Neurodegenerative Diseases
Vigil Neuroscience
Harnessing the power of microglia to transform treatments for neurodegenerative diseases
Alector
We are on a mission to make brain disorders history.
Character Biosciences
A patient-driven drug discovery platform for diseases of aging
ReviR Therapeutics
Improve human health by Revising drug discovery using RNA and AI technologies
About Passage Bio
Passage Bio, founded in 2017 and headquartered in the United States, is a clinical stage genetic medicines company dedicated to improving the lives of patients with neurodegenerative diseases. The company operates within the Biotechnology, Health Care, and Health and Wellness industries. Their mission, encapsulated by...
Development of genetic medicines, Clinical trials for CNS disorders, Gene therapy solutions
Patients with neurodegenerative diseases, Healthcare professionals specializing in CNS disorders, Biotech and pharmaceutical investors
Neurodegenerative Diseases, Genetic Medicines, Clinical Stage, One-time Therapies, Lysosomal Function Restoration, Progranulin Elevation, AAV-delivered Therapeutics, Monogenic CNS Diseases, Gene Therapy, Frontotemporal Dementia, Research Collaboration, Preclinical Work, Clinical Development, Regulatory Affairs, Patient Advocacy Outreach
B2B2C, B2B
One Time Purchase, Value Based Pricing, Licensing
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Passage Bio: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Passage Bio on 30 Jun 2026. The 11 companies listed here were last checked between 12 Sep 2024 and 16 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.